title: European Adrenal Insufficiency Registry (EU-AIR): a comparative observational study of glucocorticoid replacement therapy.
abstract: BACKGROUND
  Increased morbidity and mortality associated with conventional glucocorticoid replacement therapy for primary adrenal insufficiency (primary AI; estimated prevalence 93-140/million), secondary AI (estimated prevalence, 150-280/million, respectively) or congenital adrenal hyperplasia (estimated prevalence, approximately 65/million) may be due to the inability of typical glucocorticoid treatment regimens to reproduce the normal circadian profile of plasma cortisol. A once-daily modified-release formulation of hydrocortisone has been developed to provide a plasma cortisol profile that better mimics the daytime endogenous profile of cortisol. Here, we describe the protocol for the European Adrenal Insufficiency Registry (EU-AIR), an observational study to assess the long-term safety of modified-release hydrocortisone compared with conventional glucocorticoid replacement therapies in routine clinical practice (ClinicalTrials.gov identifier: NCT01661387).
  
  
  METHODS
  Patients enrolled in EU-AIR have primary or secondary AI and are receiving either modified-release or conventional glucocorticoid replacement therapy. The primary endpoints of EU-AIR are the incidence of intercurrent illness, adrenal crisis and serious adverse events (SAEs), as well as the duration of SAEs and dose changes related to SAEs. Data relating to morbidity, mortality, adverse drug reactions, dosing and concomitant therapies will be collected. Patient diaries will record illness-related dose changes between visits. All decisions concerning medical care are made by the registry physician and patient. Enrolment is targeted at achieving 3600 patient-years of treatment (1800 patient-years per group) for the primary analysis, which is focused on determining the non-inferiority of once-daily modified-release replacement therapy compared with conventional glucocorticoid therapy.
  
  
  RESULTS
  Recruitment began in August 2012 and, as of March 2014, 801 patients have been enrolled. Fifteen centres are participating in Germany, the UK and Sweden, with recruitment soon to be initiated in the Netherlands.
  
  
  CONCLUSIONS
  EU-AIR will provide a unique opportunity not only to collect long-term safety data on a modified-release preparation of glucocorticoid but also to evaluate baseline data on conventional glucocorticoid replacement. Such data should help to improve the treatment of AI.
authors.forename: Bertil
authors.initials: B
authors.lastname: Ekman
authors.affiliation: ViroPharma Incorporated, Exton, Pennsylvania, USA. David.Fitts@viropharma.com.
authors.forename: David
authors.initials: D
authors.lastname: Fitts
authors.forename: Claudio
authors.initials: C
authors.lastname: Marelli
authors.forename: Robert D
authors.initials: RD
authors.lastname: Murray
authors.forename: Marcus
authors.initials: M
authors.lastname: Quinkler
authors.forename: Pierre M J
authors.initials: PM
authors.lastname: Zelissen
mesh_terms: D000293:Adolescent; D000312:Adrenal Hyperplasia, Congenital / Q000188:drug therapy* / Q000378:metabolism; D000309:Adrenal Insufficiency / Q000188:drug therapy* / Q000378:metabolism; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D002940:Circadian Rhythm / Q000502:physiology; D005060:Europe; D005260:Female; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000627:therapeutic use*; D020249:Hormone Replacement Therapy; D006801:Humans; D006854:Hydrocortisone / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009017:Morbidity; D011379:Prognosis; D055815:Young Adult
chemical_list: D005938:Glucocorticoids; D006854:Hydrocortisone